AbbVie Stock News

In recent days, financial market participants have remained pessimistic about AbbVie's prospects, mainly due to the data on clinical outcomes related to emraclidine. However, I believe Mr. Market overreacted to this news, given the increase in dividend payments and the full-year non-GAAP EPS. AbbVie continues to be a leader in the global immunology market, thanks in part to the strong performan...

AbbVie stock popped Friday after an analyst upgraded it on the remaining opportunity for its Cerevel takeover despite a huge misstep. The post AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback appeared first on Investor's Business Daily.

Given its better prospects, we believe that AbbVie stock (NYSE: ABBV) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). Both AbbVie and J&J trade at 15x forward expected earnings.

Investment activity in October focused on Business Development Companies, with $1,300 added to the market. Adjusted dividend income in October of $789, up 25% Y/Y and up 11% sequentially. Main picks included Blackstone Secured Lending, Goldman Sachs BDC, and Midcap Financial Investment Corporation.

Where Will AbbVie Be in 5 Years?

The current market presents a complex mix of opportunities and risks, influenced by the Trump presidency, Fed policies, and elevated valuations. These factors require careful stock selection. I am focusing on sectors with strong recovery potential and long-term tailwinds, such as transportation and defense, while considering valuation and growth potential. My picks include high-quality, dividen...

Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip

ELAHERE is the first and only novel therapy approved in the European Union specifically for patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer ELAHERE represents the first treatment to demonstrate an overall survival benefit in a Phase 3 trial in platinum-resistant ovarian cancer compared with chemotherapy VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the companion di...